INVO Fertility, Inc 8-K, filed May 18, 2021
INVO Fertility, Inc. (IVF)
About this 8-K
INVO Fertility, Inc filed this 8-K on May 18, 2021, reporting on events of May 17, 2021.
Items reported
- Item 2.02: Financial results
- Item 9.01: Financial statements and exhibits
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT PURSUANT
TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported): May 17, 2021
INVO BIOSCIENCE, INC.
(Exact name of registrant as specified in charter)
| Nevada | 001-39701 | 20-4036208 | ||
(State or other jurisdiction of incorporation) |
(Commission File Number) |
(IRS Employer Identification No.) |
5582 Broadcast Court Sarasota, Florida |
34240 | |
| (Address of principal executive offices) | (Zip Code) |
Registrant’s telephone number, including area code: (978) 878-9505
|
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
| [ ] | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| [ ] | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| [ ] | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| [ ] | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading symbol(s) | Name of each exchange on which registered | ||
| Common Stock, $0.0001 par value per share | INVO | The Nasdaq Stock Market LLC |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1934 (§240.12b-2 of this chapter)
Emerging growth company [ ].
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. [ ]
Item 2.02. Results of Operations and Financial Condition.
On May 17, 2021, INVO Bioscience, Inc. (the “Company”) issued a press release announcing financial results for the three months ended March 31, 2021. The text of the press release is furnished as Exhibit 99.1 to this current report.
The information in this Item 2.02 and Exhibit 99.1 hereto shall not be deemed “filed” for the purposes of or otherwise subject to the liabilities under Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). Unless expressly incorporated into a filing of the Company under the Securities Act of 1933, as amended, or the Exchange Act, the information contained in this Item 2.02 and Exhibit 99.1 hereto shall not be incorporated by reference into any Company filing, whether made before or after the date hereof, regardless of any general incorporation language in such filing.
Item 9.01 Financial Statements and Exhibits
(d) Exhibits.
| Exhibit No. | Description | |
| 99.1 | Press Release dated May 17, 2021. |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
| INVO BIOSCIENCE, INC. | ||
| By: | /s/ Steven Shum | |
| Name: | Steven Shum | |
| Title: | Chief Executive Officer | |
| Dated May 17, 2021 | ||
Exhibit 99.1
INVO Bioscience Reports First Quarter 2021 Financial and Operating Results and Provides Business Update
Company to Host Conference Call Today at 4:30pm ET (Details Below)
SARASOTA, Fla., May 17, 2021 — INVO Bioscience, Inc. (Nasdaq: INVO), a medical device company focused on creating alternative treatments for patients diagnosed with infertility and developers of INVOcell®, the world’s only in vivo Intravaginal Culture System, today announced financial results for the first quarter of 2021 ended March 31, 2021 and provides a business update.
Recent Operational Highlights
| ● | Signed an agreement to open the first U.S.-based INVOcell clinic, to be located in Birmingham, Alabama with an expected opening in the second half of 2021. The Birmingham facility will be a joint venture with a group of experienced reproductive specialists who have been strong advocates and successful adopters of the INVOcell solution. | |
| ● | Signed a partnership agreement with Lyfe Medical, LLC focused on the expansion of the INVOcell solution in Northern California. Lyfe Medical will establish and operate a clinic in the San Francisco Bay Area to offer the INVO procedure to its patients while INVO Bioscience will establish and operate the embryology center to provide laboratory services in connection with the INVO procedure provided by Lyfe Medical to its patients. | |
| ● | Regulatory approval received for INVOcell in Mexico in February 2021, allowing partner to target clinic opening in second half of 2021. | |
| ● | Signed additional international agreements as well as began selling direct into Spain fertility clinics to complement the amended U.S. commercialization agreement with Ferring. | |
| ● | Regular and active training sessions being held with distributors in various parts of the world and initial INVOcell cycles already being performed and initiated in Spain and Malaysia. | |
| ● | Recent peer-reviewed publication further demonstrates excellent real-world success rates utilizing INVOcell and provides further clinical validation to support ongoing commercialization and partnering efforts - Real-world experience with intravaginal culture using INVOCELL: an alternative model for infertility treatment - F&S Reports (fertstertreports.org) | |
| ● | Building substantial expertise in global marketing and brand building through the addition of current Senior Advisor at McKinsey & Co. former Global Chief Marketing Officer of Uber and Beam Suntory, Rebecca Messina joining the Board of Directors, and a 15-year women’s health veteran, Meryle Lynn Chamberlain joining as the newly created position of Director of Marketing. | |
| Financial Highlights | ||
| ● | Revenue increased approximately 165% to $684,523 for the quarter ended March 31, 2021 compared to $258,571 for the quarter ended March 31, 2020. | |
| ● | Net loss for the first quarter of 2021 was approximately $(2.5) million, which included approximately $(1.4) million of non-cash charges primarily related to the debt discount amortization and stock-based compensation. | |
| ● | Adjusted EBITDA for the first quarter of 2021 was $(981,002), which included approximately $224,000 of JV start-up costs, compared to $(625,154) in the prior year’s first quarter (see Adjusted EBITDA Table). | |
| ● | As of March 31, 2021, the Company had a cash position of approximately $8.4 million, with additional $504,000 in account receivables received subsequent to quarter end. |
Management Discussion
“This was an exciting start to the year 2021 for INVO Bioscience as we advanced our INVO Clinic strategy with the signing of our first U.S.-based INVOcell exclusive facility in Birmingham, Alabama, the signing of a partnership agreement to establish and operate a center in Northern California, and the completion of our product registration in Mexico. We expect these initial centers to become operational in the second half of the year,” commented Steve Shum, Chief Executive Officer of INVO Bioscience. “Throughout this year, we have expanded our real-world experience data and positive results with INVOcell, enhanced our online training tools, materials, and capabilities and have experienced a substantial increase in active training sessions for our international partners and distributors. We believe the combination of strong commercialization partnerships and company-owned clinics, both in the U.S. and around the world, is key to expanding INVOcell’s adoption within the fertility industry.”
“In addition to the progress made executing new commercialization agreements, we have strengthened our marketing capabilities to support the INVOcell-only centers and our growing number of distribution partners. Meryle Lynn Chamberlain, a tenured women’s health and fertility solution marketing professional, joined us as Director of Marketing in March 2021, while Rebecca Messina, current Senior Advisor at McKinsey & Co. and former Global Chief Marketing Officer at both Uber and Beam Suntory joined our board of directors in April 2021. As we look to increase access to care and expand fertility treatment across the globe, our market positioning and overall strategies are more important than ever. The addition of Meryle Lynn and Rebecca will substantially enhance our ability to successfully accomplish these goals.”
“As we look to the remainder of 2021, we have set a number of key objectives, including the opening of our first company-owned clinics in Mexico and the United States. Additionally, we will seek to build our international revenues this year through our growing list of international distribution partners as they finish training, and we complete local product registration requirements. Of note, we are extremely pleased to see the initial INVO procedures performed recently in Spain and Malaysia, which reflects the groundwork done by our team in these specific markets, which we believe will help in further expanding the overall awareness of the potential outside of the U.S. Finally, we are continuing to advance our 5-day label expansion efforts with the FDA in the U.S. market with a goal of completing this effort in 2021. It remains our belief that there is strong global demand for fertility services and INVOcell is well-positioned through our growing, global footprint to play a key role in helping to turn the dream of creating a family for millions of people around the world into a reality through our accessible, efficient, and affordable fertility treatment.”
Financial Results
Revenue for the three months ended March 31, 2021 was $684,523, compared to $258,571 for the same three-month period in 2020, an increase of approximately 165%. The increase was the result of sales to Ferring related to satisfying the minimum purchase requirements for 2020.
Gross margin reported for the three months ended March 31, 2021 was approximately 91% compared to approximately 88% for the three months ended March 31, 2020.
Selling, general and administrative expenses for the three months ended March 31, 2021 were approximately $2.1 million compared to approximately $1.6 million for the three months ended March 31, 2020. The increase of approximately $0.5 million or 33% was primarily the result of approximately $0.2 million in startup costs related to clinic joint ventures as well as approximately $0.2 million in increased personnel and consulting expenses. We incurred approximately $0.6 million of stock-based compensation expense in the period.
We began to fund additional research and development efforts in 2020 as part of our 5-day label expansion efforts, and also submitted additional trademark and patent filings. R&D expenses were $66,267 for the three months ended March 31, 2021 compared to $30,050 for the three months ended March 31, 2020.
Interest expense and financing fees were approximately $0.9 million for the three months ended March 31, 2021, compared to approximately $0.05 million for the three months ended March 31, 2020. The increase was primarily non-cash and due to an increase in amortization of debt discount, debt issuance costs and interest on the 2020 Convertible Notes.
Net loss for the three months ended March 31, 2021 was approximately $(2.5) million compared to approximately $(1.4) million for the three months ended March 31, 2020. The increase in net loss was due to increased operating expenses and interest expense. Approximately $0.8 million of this increase was related to non-cash debt amortization expense along with approximately $0.2 million in startup costs related to joint ventures.
Adjusted EBITDA (see Adjusted EBITDA Table) for the three months ended March 31, 2021 was $(981,002), compared to adjusted EBITDA of $(625,154) for the three months ended March 31, 2020.
As of March 31, 2021, the Company had approximately $8.4 million in cash compared to approximately $0.4 million on March 31, 2020.
Use of Non-GAAP Measure
Adjusted EBITDA is a non-GAAP measure. This measure is not intended to be a substitute for those financial measures reported in accordance with GAAP. Adjusted EBITDA has been included because management believes that, when considered together with the GAAP figures, it provides meaningful information related to our operating performance and liquidity and can enhance an overall understanding of financial results and trends. Adjusted EBITDA may be calculated by us differently than other companies that disclose measures with the same or similar terms. See our attached financials for a reconciliation of this non-GAAP measure to the nearest GAAP measure.
Conference Call Details
INVO Bioscience has scheduled a conference call for Monday, May 17, 2021, at 4:30 pm ET (1:30 pm PT) to review these results and recent events. Interested parties can access the conference call by dialing (833) 756-0861 or (412) 317-5751 or can listen via a live Internet webcast at https://www.webcaster4.com/Webcast/Page/2162/40939, which is also available in the Investor Relations section of the Company’s website at https://www.invobioscience.com/investors/.
A teleconference replay of the call will be available through May 24, 2021 at (877) 344-7529 or (412) 317-0088, confirmation #10155249. A webcast replay will be available in the Investor Relations section of the Company’s website at https://www.invobioscience.com/investors/ for 90 days.
About INVO Bioscience
We are a medical device company focused on creating simplified, lower-cost treatments for patients diagnosed with infertility. Our solution, the INVO® Procedure, is a revolutionary in vivo method of vaginal incubation that offers patients a more natural and intimate experience. Our lead product, the INVOcell®, is a patented medical device used in infertility treatment and is considered an Assisted Reproductive Technology (ART). The INVOcell® is the first Intravaginal Culture (IVC) system in the world used for the natural in vivo incubation of eggs and sperm during fertilization and early embryo development, as an alternative to traditional In Vitro Fertilization (IVF) and Intrauterine Insemination (IUI). Our mission is to increase access to care and expand fertility treatment across the globe with a goal to lower the cost of care and increase the availability of care. For more information, please visit http://invobioscience.com/
Safe Harbor Statement
This release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The Company invokes the protections of the Private Securities Litigation Reform Act of 1995. All statements regarding our expected future financial position, results of operations, cash flows, financing plans, business strategies, products and services, competitive positions, growth opportunities, plans and objectives of management for future operations, as well as statements that include words such as “anticipate,” “if,” “believe,” “plan,” “estimate,” “expect,” “intend,” “may,” “could,” “should,” “will,” and other similar expressions are forward-looking statements. All forward-looking statements involve risks, uncertainties and contingencies, many of which are beyond our control, which may cause actual results, performance, or achievements to differ materially from anticipated results, performance, or achievements. Factors that may cause actual results to differ materially from those in the forward-looking statements include those set forth in our filings at www.sec.gov. We are under no obligation to (and expressly disclaim any such obligation to) update or alter our forward-looking statements, whether as a result of new information, future events or otherwise.
| For more information, please contact: | |
| INVO Bioscience | |
| Steve Shum, CEO | |
| 978-878-9505 | |
| steveshum@invobioscience.com | |
| Investors | |
| Lytham Partners, LLC | |
| Robert Blum | |
| 602-889-9700 | |
| INVO@lythampartners.com |
INVO BIOSCIENCE, INC.
CONSOLIDATED BALANCE SHEETS
(UNAUDITED)
| March 31, | December 31, | |||||||
| 2021 | 2020 | |||||||
| ASSETS | ||||||||
| Current assets | ||||||||
| Cash | $ | 8,423,236 | $ | 10,097,760 | ||||
| Accounts receivable | 527,651 | 21,699 | ||||||
| Inventory | 268,349 | 265,372 | ||||||
| Prepaid expenses and other current assets | 363,969 | 157,700 | ||||||
| Total current assets | 9,583,205 | 10,542,531 | ||||||
| Property and equipment, net | 129,679 | 132,206 | ||||||
| Capitalized patents, net | 22,606 | 5,427 | ||||||
| Lease right of use | 73,644 | 79,319 | ||||||
| Trademarks | 100,885 | 89,536 | ||||||
| Notes receivable | 280,160 | - | ||||||
| Other assets | - | 240 | ||||||
| Investment in joint ventures | - | 98,084 | ||||||
| Total other assets | 477,295 | 272,606 | ||||||
| Total assets | $ | 10,190,179 | $ | 10,947,343 | ||||
| LIABILITIES AND STOCKHOLDERS’ EQUITY | ||||||||
| Current liabilities | ||||||||
| Accounts payable and accrued liabilities, including related parties | $ | 512,044 | $ | 328,927 | ||||
| Accrued compensation – related party | 267,390 | 527,326 | ||||||
| Deferred revenue, current portion | 714,286 | 714,286 | ||||||
| Lease liability, current portion | 23,061 | 22,707 | ||||||
| Notes payable – Payroll Protection Program | 157,620 | 157,620 | ||||||
| Convertible notes, net | 185,458 | 536,063 | ||||||
| Income taxes payable | - | 1,062 | ||||||
| Total current liabilities | 1,859,859 | 2,287,991 | ||||||
| Lease liability, net of current portion | 52,789 | 58,634 | ||||||
| Deferred revenue, net of current portion | 2,678,571 | 2,857,143 | ||||||
| Deferred tax liability | 469 | 469 | ||||||
| Total liabilities | 4,591,688 | 5,204,237 | ||||||
| Stockholders’ equity | ||||||||
| Common Stock, $.0001 par value; 125,000,000 shares authorized; 10,424,229 and 9,639,268 issued and outstanding as of March 31, 2021 and December 31, 2020, respectively | 1,042 | 964 | ||||||
| Additional paid-in capital | 40,287,000 | 37,978,224 | ||||||
| Accumulated deficit | (34,689,551 | ) | (32,236,082 | ) | ||||
| Total stockholders’ equity | 5,598,491 | 5,743,106 | ||||||
| Total liabilities and stockholders’ equity | $ | 10,190,179 | $ | 10,947,343 | ||||
INVO BIOSCIENCE, INC.
CONSOLIDATED STATEMENTS OF OPERATIONS
(UNAUDITED)
| For the Three Months Ended | ||||||||
| March 31, | ||||||||
| 2021 | 2020 | |||||||
| Revenue: | ||||||||
| Product revenue | $ | 505,952 | $ | 80,000 | ||||
| License revenue | 178,571 | 178,571 | ||||||
| Total revenue | 684,523 | 258,571 | ||||||
| Cost of goods sold: | ||||||||
| Production costs | 60,314 | 27,563 | ||||||
| Depreciation | 2,431 | 2,431 | ||||||
| Total cost of goods sold | 62,745 | 29,994 | ||||||
| Gross profit | 621,778 | 228,577 | ||||||
| Selling, general and administrative expenses | 2,115,303 | 1,595,046 | ||||||
| Research and development | 66,267 | 30,050 | ||||||
| Total operating expenses | 2,181,570 | 1,625,096 | ||||||
| Loss from operations | (1,559,792 | ) | (1,396,519 | ) | ||||
| Other income (expense): | ||||||||
| Interest income | 2,013 | - | ||||||
| Interest expense | (895,226 | ) | (47,873 | ) | ||||
| Foreign currency exchange loss | (464 | ) | - | |||||
| Total other expenses | (893,677 | ) | (47,873 | ) | ||||
| Loss before income taxes | (2,453,469 | ) | (1,444,392 | ) | ||||
| Provision for income taxes | - | - | ||||||
| Net loss | $ | (2,453,469 | ) | $ | (1,444,392 | ) | ||
| Net loss per common share: | ||||||||
| Basic | $ | (0.25 | ) | $ | (0.29 | ) | ||
| Diluted | $ | (0.25 | ) | $ | (0.29 | ) | ||
| Weighted average number of common shares outstanding: | ||||||||
| Basic | 9,888,025 | 4,917,997 | ||||||
| Diluted | 9,888,025 | 4,917,997 | ||||||
| Adjusted EBITDA | ||||||||
| For the Three Months Ended~ | ||||||||
| March 31, | ||||||||
| 2021 | 2020 | |||||||
| Net loss | $ | (2,453,469 | ) | $ | (1,444,392 | ) | ||
| Add: | ||||||||
| Interest expense | 35,071 | 47,873 | ||||||
| Stock-based compensation | 192,064 | 341,463 | ||||||
| Stock option expense | 376,523 | 381,475 | ||||||
| Amortization of debt discount | 860,155 | 39,918 | ||||||
| Depreciation and amortization | 8,654 | 8,509 | ||||||
| Adjusted EBITDA | $ | (981,002 | ) | $ | (625,154 | ) | ||